ReviewExpert review of clinical pharmacology2025
The importance of specificity of drug treatment in head and neck cancer: current developments in personalized medicine to improve safety and tolerability.
Review in Expert review of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.International journal of pharmaceutics: X · 2026Review
- Cancer-associated fibroblasts as a target in head and neck squamous cell carcinoma: bridging mechanisms to therapy with drugs, adjuvants, and nanotechnology.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionHead and neck squamous cell carcinoma (HNSCC) remains a treatment challenge, with frequent recurrences following localized disease and guarded outcomes in recurrent/metastatic (R/M) settings. While cytotoxic therapy and immune checkpoint inhibitors (ICIs) have produced incremental survival benefits, many patients still exhibit limited response or acquire resistance to treatment, highlighting a critical need for more personalized and novel therapeutic strategies. AREAS COVERED: This review discusses personalized therapy approaches in HNSCC from 2020 to 2025, focusing on immune checkpoint blockade and newer therapeutic modalities. Additionally, this review highlights key biomarkers that are currently being evaluated for predictive and prognostic value in HNSCC. The literature was sourced through PubMed, Google Scholar, and conference abstracts from ASCO, ESMO, and AACR, covering publications from January 2020-June 2025, with a focus on peer-reviewed trials and translational studies in human subjects. EXPERT OPINION: The future of HNSCC treatment lies in the development of novel treatment combinations integrating immunotherapy using immune checkpoint blockade with newer therapeutic approaches. Understanding which agents to use, and when in the course of treatment, stands as a challenge that will shape the future of precision therapy for HNSCC, with integration of biomarkers promising to guide this transition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.